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Summary
Objective: The normal structure and function of articular cartilage are the result of a precisely balanced interaction between anabolic and
catabolic processes. The transforming growth factor-beta (TGF-b) family of growth factors generally exerts an anabolic or repair response;
in contrast, proinﬂammatory cytokines such as interleukin 1 beta (IL-1b) and tumor necrosis factor-alpha (TNF-a) exert a strong catabolic
effect. Recent evidence has shown that IL-1b, and TNF-a, and the TGF-b signaling pathways share an antagonistic relationship. The aim
of this study was to determine whether the modulation of the response of articular chondrocytes to TGF-b by IL-1b or TNF-a signaling path-
ways occurs through regulation of activity and availability of mothers against DPP (Drosophila) human homologue (Smad) proteins.
Methods: Human articular chondrocytes isolated from knee joints from patients with osteoarthritis (OA) or normal bovine chondrocytes were
cultured in suspension in poly-(2-hydroxyethyl methacrylate)-coated dishes with either 10% fetal bovine serum media or serum-deprived
media 6 h before treatment with IL-1b alone, TNF-a alone or IL-1b followed by TGF-b. Nuclear extracts were examined by electrophoretic
mobility-shift assays (EMSA) for nuclear factor-kappa B (NF-kB) and Smad3/4 deoxyribonucleic acid (DNA) binding. Nuclear extracts were
also subjected to the TranSignal Protein/DNA array (Panomics, Redwood City, CA) enabling the simultaneous semiquantitative assessment
of DNA-binding activity of 54 different transcription factors. Nuclear phospho-Smad2/3 and total Smad7 protein expression in whole cell ly-
sates were studied by Western blot. Cytoplasmic Smad7, type II collagen alpha 1 (COL2A1), aggrecan and SRY-related high mobility
group-Box gene 9 (SOX-9) mRNA expression were measured by real-time polymerase chain reaction (PCR).
Results: The DNA-binding activity of Smad3/4 in the TranSignal Protein/DNA array was downregulated by TNF-a (46%) or IL-1b treatment
(42%). EMSA analysis showed a consistent reduction in Smad3/4 DNA-binding activity in human articular chondrocytes treated with IL-1b
or TNF-a. TGF-b-induced Smad3/4 DNA-binding activity and Smad2/3 phosphorylation were also reduced following pretreatment with IL-
1b in human OA and bovine chondrocytes. Real-time PCR and Western blot analysis showed that IL-1b partially reversed the TGF-b stimu-
lation of Smad7 mRNA and protein levels in TGF-b-treated human OA cells. In contrast, TGF-b-stimulated COL2A1, aggrecan, and SOX-9
mRNA levels were abrogated by IL-1b.
Conclusions: IL-1b or TNF-a exerted a suppressive effect on Smad3/4 DNA-binding activity in human articular chondrocytes, as well as on
TGF-b-induced stimulation of Smad3/4 DNA-binding activity and Smad2/3 phosphorylation in human OA and bovine articular chondrocytes.
IL-1b partially reversed the increase in TGF-b-stimulated Smad7 mRNA or protein levels suggesting that Smad7 may not be involved in the
suppression of TGF-b signaling induced by IL-1b or TNF-a in articular chondrocytes. The balance between the IL-1b or TNF-a and the
TGF-b signaling pathways is crucial for maintenance of articular cartilage homeostasis and its disruption likely plays a substantial role in
the pathogenesis of OA.
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Cartilage
Repair
SocietyIntroduction
Articular cartilage is a complex tissue covering the bony sur-
face of all diarthrodial joints, providing a low friction surface
that enables the joints to move freely, bear load and absorb
shock. The interaction between anabolic and catabolic pro-
cesses determines articular cartilage homeostasis. In the
normal situation, this interplay results in a precise balance
between extracellular matrix synthesis and its degradation.
In osteoarthritis (OA), the balance between anabolism and
catabolism is altered resulting in the breakdown of the func-
tionality of the articular cartilage and hence the joint itself.
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crine anabolic and catabolic signals and the precise inter-
play of these pathways is crucial for the normal function of
the tissue. Among these signals are the proinﬂammatory cy-
tokines interleukin 1 beta (IL-1b)/tumor necrosis factor-alpha
(TNF-a), and the transforming growth factor-beta (TGF-b)
family of growth factors, which play critical roles in articular
chondrocyte metabolism and differentiation and are also im-
plicated in the pathological mechanisms of OA.
TGF-b family members regulate chondrocyte function
during development and participate in the pathogenesis of
cartilage disorders1. TGF-b can stimulate mesenchymal
cells to undergo chondrogenesis and to inhibit chondrocyte
hypertrophic differentiation2e7. Signiﬁcantly, TGF-b gener-
ally exerts a beneﬁcial anabolic or ‘‘repair’’ response on ar-
ticular cartilage. TGF-b can elicit an increase in aggrecan
and collagen gene expression and also prevent loss of pro-
teoglycan in articular cartilage during experimental OA8e11.67
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following exogenous TGF-b administration, including osteo-
phyte formation12,13. TGF-b signaling proceeds through
type I/II receptor serine/threonine-kinases that phosphory-
late the regulatory mothers against DPP (Drosophila) hu-
man homologue (Smad) (R-Smad: Smads1, 2, 3, 5 and
8)14,15. Remarkably, a decrease in TGF-b receptor II ex-
pression has been described in experimental OA supporting
the notion that an alteration in the TGF-b signaling cascade
could have a potential role in cartilage breakdown16. Upon
phosphorylation, the R-Smads form heterodimers with
co-Smads (Smad4) and translocate to the nucleus, where
they can regulate the transcription of target genes along
with other transcriptional co-regulators15,17. Another class
of Smad proteins, the inhibitory Smads (I-Smads; Smads6
and 7) can abrogate TGF-b signaling by either causing
the degradation of R-Smads18,19, competing with R-Smads
for association with type I receptors, or functioning as adap-
tors to recruit Smurfs (E3 ubiquitin ligases) to the TGF-b
receptor complex, thus, mediating its degradation20. Fur-
thermore, in the nucleus an Skp1-cullin-F box protein E3
(SCF-E3) ubiquitin ligase complex is thought to mediate
the ubiquitination of Smad3 and its subsequent transport
to the cytoplasm for degradation21.
Articular cartilage also responds to and produces sev-
eral types of proinﬂammatory cytokines, particularly during
the development of OA. In contrast to the TGF-b effects,
the proinﬂammatory cytokines IL-1b and TNF-a exert
a strong catabolic effect on articular cartilage22e24. IL-1b
and TNF-a upregulate the chondrocyte production of fac-
tors associated with cartilage matrix destruction such as
metalloproteinases, inducible enzymes, free radicals,
etc., while also inhibiting cartilage matrix synthesis
through repression of cartilage-speciﬁc gene expression
such as type II collagen, type IX collagen, aggrecan,
link protein, SRY-related high mobility group-Box gene 9
(SOX-9), etc.25e27. IL-1b and TNF-a signal through a di-
verse set of pathways, however, the two main pathways
that they share in common are the mitogen activated pro-
tein (MAP) kinase pathway which leads to the activation
of transcription factors such as activating protein-1 (AP-
1), activating transcription factor (ATF) and member of
ETS oncogene family (Elk-1), and the inhibitory kappa
B (IkB) kinase pathway which leads to the activation of
nuclear factor-kappa B (NF-kB)28e30.
Recent studies have demonstrated the existence of an
antagonistic relationship between the IL-1b or TNF-a and
the TGF-b signaling pathways in numerous cell types. In
human dermal ﬁbroblasts, TNF-a inhibits the TGF-b path-
way through activation of AP-1 transcription factor31.
Further investigation has shown that inhibition of the TGF-b
pathway by TNF-a through AP-1 activation is dependent on
the Jun N-terminal kinase (JNK) kinases32. Interestingly,
a different mechanism for Smad inhibition by IL-1b/TNF-a
has been reported in ﬁbroblasts established from
Rel-/- mice. This mechanism involves the induction of the
expression of the inhibitory Smad7 gene through the NF-kB
pathway33. A third mechanism may be present in osteo-
blasts from individuals with inﬂammatory bone disorders.
In these cases, TNF-a upregulates Smurf 1 and Smurf 2 ex-
pression promoting the proteasomal degradation of the os-
teoblast transcription factor Runx234. Thus, several different
speciﬁc mechanisms exist for the regulation of TGF-b sig-
naling by proinﬂammatory cytokines. However, the molecu-
lar mechanisms by which proinﬂammatory cytokines modify
and/or regulate the TGF-b signaling pathway in articular
chondrocytes are not fully understood.The aim of this study was to determine whether IL-1b and
TNF-a modulate the response of human articular chondro-
cytes to TGF-b through regulation of activity and availability
of Smad proteins. However, in some of the experiments we
have also examined bovine articular chondrocytes. Al-
though, it is obvious that there are numerous signiﬁcant dif-
ferences between human and animal chondrocytes,
chondrocytic cells of animal origin have been extensively
utilized in the past to complement the understanding of
biologic events that occur in human OA cartilage. The oste-
oarthritic process alters the response of articular chondro-
cytes to different stimuli such as growth factors, cytokines,
mechanical stress, etc.; therefore, the use of OA human
chondrocytes to study those biologic events in this disease
is crucial. However, the shortage of chondrocytes and the
high variability between cells obtained from different
patients often render it very difﬁcult or truly impossible to
perform large numbers of experiments or complex studies
requiring large number of cells such as the ones we
describe here with human chondrocytes.
Materials and methods
ISOLATION AND CULTURE OF HUMAN OA
AND BOVINE CHONDROCYTES
Human articular cartilage was obtained from the tibial pla-
teaus and femoral condyles of patients with OA who under-
went knee-joint replacement surgery at Thomas Jefferson
University Hospital, following procedures approved by the
Institutional Review Board. Fresh bovine articular cartilage
from adult (24e48 m) carpal and metacarpal joints was pur-
chased from Animal Technologies, Inc. (Tyler, TX). The
chondrocytes were isolated from cartilage tissue as previ-
ously described35,36. Brieﬂy, to remove adherent ﬁbrous tis-
sues, the cartilage was incubated in Hanks’ medium
containing trypsin and bacterial collagenase (2 mg/ml
each) for 1 h at 37C. The medium was discarded and the
tissue fragments minced and digested overnight at 37C
in Dulbecco’s minimum essential medium (DMEM) with
4.5 g/l glucose containing 10% fetal bovine serum (FBS)
and 0.5 mg/ml bacterial collagenase. The released cells
were ﬁltered through a 70 mm nylon cell strainer and were
collected by centrifugation at 250 g for 5 min and washed
four times with collagenase-free medium. Isolated chondro-
cytes were immediately frozen in freezing media (90% FBS,
10% dimethyl sulfoxide (DMSO)) and stored for future ex-
periments. To preserve the differentiated phenotype, cells
were thawed and plated in poly-(2-hydroxyethyl methacry-
late) (polyHEMA)-coated dishes at a density of 1 106/ml
as previously described35,36. The cells were allowed to re-
cover for 48 h at which time they were utilized for experi-
ments. All cultures were maintained in DMEM containing
10% FBS, 2 mM glutamine, 1% vitamin supplements,
100 U/ml penicillin, 100 mg/ml streptomycin, 2.5 mg/ml am-
photericinB, and50 mg/ml ascorbic acid.Culturesweremain-
tained at 37C in 5% CO2 and 95% air (21% O2). One night
before treatment with cytokines the FBS in the bovine articu-
lar chondrocytes’ culture media was reduced to 1%, and the
followingday, the culturemediawas serum-free for 6 hbefore
treatment with cytokines. In initial experiments human OA
chondrocytes were cultured in 10% FBSmedia without cyto-
kines or were treated with either 10 ng/ml IL-1b or 10 ng/ml
TNF-a for 2 h. In further experiments human OA and bovine
articular chondrocytes were treated with 10 ng/ml IL-1b or
pretreated with 10 ng/ml IL-1b and then treated with 10 ng/
ml TGF-b as shown schematically in Fig. 1. TGF-b and
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purchased from Peprotech (Rocky Hill, NJ).
PREPARATION OF NUCLEAR EXTRACTS AND
ELECTROPHORETIC MOBILITY-SHIFT ASSAYS (EMSA)
Nuclear extracts were prepared from isolated chondro-
cytes according to the method of Dignam et al.37, using
the CellLytic NuCLEAR extraction kit (Sigma) as described
previously38,39. Brieﬂy, cells were placed in hypotonic buffer
(10 mM N-2-Hydroxyethylpiperazine-N0-2-Ethanesulfonic
acid (HEPES) [pH 7.9], 1.5 mM MgCl2, 10 mM KCl, and
0.5 mM dithiothreitol (DTT)) and incubated on ice for
15 min. Igepal CA-630 was added to a ﬁnal concentration
of 0.6% and the mixture was vortexed vigorously for 10 s.
Nuclei were recovered by centrifugation at 3300 g for
30 s at 4C and extracted in buffer containing 20 mM
HEPES pH 7.9, 0.42 M NaCl, 25% glycerol, 1.5 mM
MgC12, 0.2 mM ethylenediamine tetraacetic acid (EDTA),
and 0.5 mM DTT for 30 min at 4C by gentle shaking.
The extract was centrifuged for 15 min at 25,000 g,
and the supernatant was then frozen at 70C. All
buffers contained a protease inhibitor mixture (2 mM 4-
(2-aminoethyl) benzenesulfonylﬂuoride, 1.4 pM trans-
epoxysuccinyl-L-leucylamido[4-guanidinobutane], 130 pM
bestatin, 1 mM leupeptin, and 0.3 pM aprotinin (Sigma). Pro-
tein concentration was determined by the Bradford assay40
and optical density read by absorbance at 595 nm.
EMSA were performed as previously described with mi-
nor modiﬁcations38,39. Brieﬂy, binding reactions consisted
of 12.5 mM HEPES, pH 7.9, 50e100 mM NaCl, 5% glyc-
erol, 2 mg/ml bovine serum albumin (BSA), 2 mg polydeox-
yinosine-deoxycytosine (poly-dIdC), 10 mg BSA, 0.1 mM
EDTA, 0.1 mM DTT, 1 ng of 32P-end labeled double
stranded deoxyribonucleic acid (DNA) probe and 5e15 mg
of nuclear protein. Binding reactions were incubated for
30 min at 21C and then loaded onto 5% acrylamide-
0.25 TriseborateeEDTA (TBE) gels and electrophoresed
at 200 V for 2 h. EMSA were carried out with consensus
probes speciﬁc for NF-kB and Smad3/4 from Santa Cruz
Biotechnology (Santa Cruz, CA).
TRANSCRIPTION FACTOR/DNA ARRAY
Nuclear extracts were subjected to the TranSignal Protein/
DNA array I (Panomics, Redwood City, CA) according to the
manufacturer’s speciﬁcations. This assay enables the
TGF-β
IL-1β
IL-1β TGF-β
No treatment
0’ 30’ 60’
Control*
TGF-β 30 min*
IL-1β 30 min pre-treat
TGF-β 30 min*
IL-1β 60 min*
Fig. 1. Diagram of the experimental design for the treatment of
human OA and bovine articular chondrocytes with either TGF-b,
IL-1b or both. All bovine articular chondrocytes were cultured in
the absence of FBS for 6 h before addition of either IL-1b or
TNF-a, whereas human OA chondrocytes were cultured in 10%
FBS media.simultaneous detection and semiquantitative comparison
of the DNA-binding activity of 54 different transcription fac-
tors from nuclear extracts from cells treated under two differ-
ent conditions. Brieﬂy, biotin-labeled DNA-binding
oligonucleotides (TranSignal Probe Mix) were incubated
with 10 mg of nuclear extract at 15C for 30 min to allow
the formation of protein (transcription factor)/DNA com-
plexes. The transcription factor/DNA complexes were sepa-
rated from the free probes by 2% agarose gel
electrophoresis in 0.5 TBE at 120 V for 15 min. The probes
in the complexes were then extracted, ethanol precipitated
and hybridized to the TranSignal Protein/DNA Array. De-
tection of signals was obtained using an enhanced chemilu-
minescence imaging system.
PREPARATION OF WHOLE CELL LYSATES
Whole cell lysates were prepared from isolated human
OA and from bovine chondrocytes by homogenization in
radioImmunoprecipitation assay (RIPA) buffer (150 mM
NaCl, 10 mM Tris, pH 7.2, 0.1% sodium-dodecyl-sulfate
(SDS), 1.0% Triton X-100, 1% deoxycholate, 5 mM EDTA)
containing the protease inhibitor mixture described above
and a phosphatase inhibitor mixture (cantharidin, bromote-
tradizole and microcystin LR) (Sigma). Cell debris was
removed by centrifugation. Protein concentration was deter-
mined by the Bradford assay40 and optical density read by
absorbance at 595 nm.
WESTERN-BLOT ANALYSIS
For Western analysis, 15e20 mg of chondrocyte nuclear
extract or 10 mg of protein cell lysate was separated by
electrophoresis on 10% SDS-polyacrylamide gels and
transferred onto 0.45 mm nitrocellulose membranes (Bio-
Rad Laboratories, Hercules, CA) in 20 mM Tris, 150 mM
glycine and 20% methanol at 40 V for 2 h at room temper-
ature. The membranes were blocked with TBS wash
solution containing 5% nonfat milk and 0.1% Tween 20
(tris-buffered saline-milk tween (TBS-MT) buffer) for 1 h
at room temperature. The transferred proteins were
reacted overnight at 4C with a rabbit polyclonal anti-
phospho-Smad2 (SER465/467) antibody (Chemicon Inter-
national, Temecula, CA) at 1/500 dilution in TBS-MT
buffer. The secondary antibody was a donkey anti-rabbit
IgG-horseradish peroxidase conjugate (1/1000 dilution;
Amersham Biosciences, Piscataway, NJ). The membranes
were washed three times for 5 min each between antibody
incubations with TBS-MT buffer. Smad7 antibody (Imge-
nex, San Diego, CA) was used at a 1/250 dilution in
TBS-MT buffer following the same protocol used for the
phospho-Smad2 antibodies. The membranes were then
stripped and reprobed against b-actin antibody (Sigma)
as a control for protein loading and transfer. The signals
on the membranes were detected using ECL detection
kit (Amersham Biosciences).
CYTOPLASMIC RNA ISOLATION AND REAL-TIME
POLYMERASE CHAIN REACTION (PCR) ANALYSIS
Preparation of cytoplasmic RNA from isolated human OA
and bovine chondrocytes was according to Schreiber
et al.41 and Gough42. Brieﬂy, after recovering the nuclei, su-
pernatants containing cytoplasm fractions were transferred
to fresh tubes with equal volumes of buffer containing
10 nM Tris pH 7.5, 7 M urea, 1% SDS, 0.3 M Na acetate
1370 J. A. Roman-Blas et al.: Modulation of TGF-b signaling in articular chondrocytesTable I
Primers for human and bovine genes utilized for real-time PCR amplification
Gene Primer sequence (50/ 30) Nucleotide location Reference*
(A) Human genes
Col2A1 AACCAGATTGAGAGCATCCG 3740e3759 NM_033150
AACGTTTGCTGGATTGGGGT 3943e3924
Aggrecan AGAATCCACCACCACCAG 6222e6239 NM_013227
ATGCTGGTGCTGATGACA 6365e6348
Smad7 GGCTTTCAGATTCCCAACTT 1021e1040 NM_005904
TCCCCTGAGGTAGATCATAG 1167e1149
SOX-9 GCGGAGGAAGTCGGTGAAGA 903e922 NM_000346
TTGGAGATGACGTCGCTGCT 1226e1207
b-Actin TCTGGCGGCACCACCATG TA 971e990 NM_001101
TTGCTGATCCACATCTGCTGG 1149e1129
(B) Bovine genes
Col2A1 ATCAACGGTGGCTTCCACT 138e157 X02420
TTCGTGCAGCCATCCTTCAG 401e382
Aggrecan GACCAGAAGCTGTGCGAGGA 6697e6716 U76615
GCCAGATCATCACCACACAG 7015e6996
Smad7 GGGCTTTCAGATTCCCAACTT 733e753 XM_616030
CTCCCAGTATGCCACCACG 804e786
SOX-9 ACGTCAAGCGGCCCATGAAC 311e330 AF278703
TCCGGGTGGTCCTTCTTGTG 512e493
Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH)
GCCATCACTGCCACCCAGAA 604e623 NM_001034034
GCGGCAGGTCAGATCCACAA 810e791
*Gene Bank Access Number.and 20 mM EDTA and 3/4 volume of phenol/chloroform
(1:1), and mixed immediately. RNA extraction was then per-
formed by vortexing, spinning at 13,000 g for 10 min, and
discarding the upper phase. The RNA was re-extracted with
an equal volume of phenol/chloroform (1:1) and then precip-
itated with 2.5 volumes of 95% ethanol and resuspended in
diethylpyrocarbonate (DEPC)-treated water.
One microgram of cytoplasmic RNA from each sample
was reverse transcribed to generate ﬁrst strand cDNA, us-
ing Superscript III reverse transcriptase and oligo-dT as
a primer (Invitrogen, Carlsbad, CA), following the manufac-
turer’s instructions. Quantitative real-time PCR was carried
out with a cDNA equivalent to 35 ng total RNA per reaction
using the QuantiTec SYBR Green PCR Kit (Qiagen, Valen-
cia, CA), according to the manufacturer’s instructions. PCR
primers were synthetized by Integrated DNA Technologies
(Coralville, IA). The primers utilized are shown in Table I.
The primers for bovine Smad7 were designed based on
the human sequence. Reactions were run in a MyiQ sin-
gle-color real-time PCR detection system (Bio-Rad Labora-
tories) under the following conditions: initial denaturation of
95C for 10 min followed by 40 cycles composed by dena-
turation at 95C for 15 s and annealing-elongation at 60C
for 1 min. For standardization, GAPDH mRNA levels were
calculated as internal controls. Negative controls were
used to show absence of carryover. Additionally, ampliﬁca-
tion products were electrophoresed on agarose gels to con-
ﬁrm the presence of unique bands with the expected size
for each amplicon. Statistical signiﬁcance was estimated
with a P value< 0.05.
Results
GLOBAL RESPONSE OF TRANSCRIPTION FACTOR
DNA-BINDING ACTIVITY IN HUMAN OA CHONDROCYTES
TREATED WITH EITHER TNF-a OR IL-1b
OA cartilage was obtained from three patients undergoing
knee-replacement surgery (60-year-old female and 67- and
79-year-old males). Chondrocytes were isolated andFig. 2. Activation of NF-kB in human OA chondrocytes. Nuclear ex-
tracts from human OA articular chondrocytes of three patients were
subjected to EMSA with consensus NF-kB double stranded oligo-
nucleotide probes. A representative example of one of the samples
is shown. Note the clear increase in NF-kB DNA-binding activity in
the cells treated with either IL-1b or TNF-a compared with control
cells.
1371Osteoarthritis and Cartilage Vol. 15, No. 12Fig. 3. Protein (transcription factor)/DNA array. Representative
images of TranSignal Protein/DNA array I blots containing 54 dif-
ferent transcription factor DNA-binding sites obtained from control
nuclear extracts or from nuclear extracts from one of the three nu-
clear extracts examined from human OA chondrocytes treated with
TNF-a or IL-1b. The transcription factors that were downregulated
in all three samples are shown in boxes. The DNAs were spotted
in duplicate in two rows (top: undiluted; bottom: dilution 1/10).
Biotinylated DNA was spotted for alignment along the right and
bottom sides of the array.cultured in suspension cultures for 60 h and then treated
with either 10 ng/ml of TNF-a or 10 ng/ml of IL-1b for 2 h fol-
lowed by preparation of nuclear extracts as described in Ma-
terials and methods section. Control samples were cultured
exactly under the same conditions except that the cytokines
were excluded. As a control for the effectiveness of cytokine
treatment, EMSA were performed with a speciﬁc probe for
NF-kB. EMSA analysis showed a marked increase in the
DNA-binding activity of NF-kB in response to cytokine treat-
ment in chondrocytes from all the three OA patients (Fig. 2).
Nuclear extracts were then screened against the TranSignal
Protein/DNA-binding array. The DNA-binding activity of
six transcription factors (E26 transformation-speciﬁc (Ets),
retinoic acid receptor (domain repeat-5) (RAR(DR-5)),
Stat4, interferon regulatory factor 1 (IRF-1), Smad3/4 and
thyroid hormone receptor (domain repeat-4) (TR(DR-4)))
was found to be downregulated in all three samples by
TNF-a treatment. Smad3/4 was reduced by 54% and
TR(DR-4) was reduced by 55% (Fig. 3 and Table II). IL-1b
treatment also resulted in the downregulation of TR(DR-4)
and Smad3/4 in all three samples by 47% and 42%, respec-
tively [Fig. 3(B) and Table III].
EFFECTS OF IL-1b, TNF-a OR TGF-b ON Smad3/4 DNA-BINDING
ACTIVITY IN HUMAN OA AND BOVINE ARTICULAR
CHONDROCYTES
To conﬁrm the consistent decrease in Smad3/4 DNA-
binding activity induced by either TNF-a or IL-1b treatment
(54% and 42%, respectively) found in the protein (transcrip-
tion factor)/DNA-binding array, human OA chondrocytes
were treated with IL-1b or TNF-a and nuclear extracts
were prepared and subjected to EMSA with a consensus
Smad3/4 double stranded probe43. The results in Fig. 4
conﬁrmed that Smad3/4 DNA-binding activity was reduced
in human OA chondrocytes treated with either TNF-a or
IL-1b as compared to control cells. In order to avoid the in-
herent variability between human OA chondrocytes ob-
tained from different donors we utilized mature bovine
articular chondrocytes. The experimental design employed
with these cells was the same as that used for human OA
cells and is shown in Fig. 1. EMSA performed with a consen-
sus NF-kB probe conﬁrmed a strong response of these
cells to IL-1b, which induced strong NF-kB DNA-binding ac-
tivity [Fig. 5(A)]. The same nuclear extracts were then sub-
jected to EMSA with the Smad3/4 consensus probe. As can
be seen in Fig. 5(B), treatment with TGF-b increased
Smad3/4 DNA-binding activity whereas pretreatment with
IL-1b reduced the TGF-b-induced Smad3/4 DNA binding.
Table II
Transcription factors downregulated in 3/3 human OA chondrocyte
samples by TNF-a
Factor Ratios* Average ratio Standard deviation
Ets 0.62 0.5 0.34 0.49 0.14
RAR(DR-5) 0.47 0.36 0.54 0.46 0.09
Stat4 0.19 0.61 0.61 0.47 0.24
IRF-1 0.67 0.64 0.32 0.54 0.19
Smad3/4 0.66 0.09 0.65 0.46 0.33
TR(DR-4) 0.47 0.65 0.22 0.45 0.21
Nuclear extracts from human OA chondrocytes treated with TNF-a
were screened against the TranSignal Protein/DNA-binding array
(Panomics, Redwood City, CA).
*Ratios indicate the intensity of binding of samples treated with
TNF-a divided by the intensity of binding of untreated samples.
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IN RESPONSE TO IL-1b PRETREATMENT
To examine whether the effects of IL-1b on TGF-b-
induced DNA-binding activity are mediated by changes in
Smad phosphorylation, Western analysis was performed
in nuclear extracts from human OA and bovine chondro-
cytes treated as depicted in Fig. 1 employing anti-Smad2/3
phospho-speciﬁc antibodies. The results in Fig. 6 show that
phosphorylation of Smad2/3 is strongly induced following
TGF-b treatment. In contrast, the phospho-Smad2/3 levels
were markedly reduced in IL-1b pretreated chondrocytes
compared with chondrocytes stimulated with TGF-b alone.
Thus, these results indicate that IL-1b pretreatment reduced
the TGF-b-induced Smad2/3 phosphorylation in human OA
and bovine chondrocytes.
Table III
Transcription factors downregulated in 3/3 human OA chondrocyte
samples by IL-1b
Factor Ratios* Average ratio Standard deviation
TR(DR-4) 0.55 0.64 0.39 0.53 0.13
Smad3/4 0.7 0.6 0.45 0.58 0.13
Nuclear extracts from human OA chondrocytes treated with IL-1b
were screened against the TranSignal Protein/DNA-binding array
(Panomics, Redwood City, CA).
*Ratios indicate the intensity of binding of samples treated with
IL-1b divided by the intensity of binding of untreated samples.
Fig. 4. EMSA showing a reduction in Smad3/4 DNA-binding activity
in human OA chondrocytes treated with either IL-1b or TNF-a
compared with control cells.REGULATION OF Smad7 mRNA/PROTEIN LEVELS IN
RESPONSE TO IL-1b PRETREATMENT
To examine the role of the inhibitory Smad7, human OA
and bovine chondrocytes were treated as shown in Fig. 1.
Real-time PCR analysis was performed for human and
bovine Smad7, type II collagen alpha 1 (COL2A1), aggre-
can, SOX-9 and actin mRNA levels. Figure 7(A) and (B)
shows that the constitutive, baseline levels of Smad7
mRNA and Smad7 protein levels were either reduced (in
bovine chondrocytes) or not signiﬁcantly affected (in hu-
man OA chondrocytes) by IL-1b treatment, whereas the
cytokine partially reversed the TGF-b-induced Smad7
mRNA and protein stimulation in the TGF-b-treated OA
human and bovine chondrocytes. In order to verify that
the chondrocytes responded to IL-1b or TGF-b the levels
of COL2A1, aggrecan, and SOX-9 mRNA were also
assessed. In all cases there was an induction of mRNA
levels following TGF-b stimulation and a decrease in this
response in cells exposed to pretreatment with IL-1b fol-
lowed by TGF-b, although the decrease in mRNA levels
of COL2A1, aggrecan and SOX-9 was more profound as
a result of IL-1b treatment alone.
Discussion
Articular cartilage responds to a host of autocrine and
paracrine anabolic and catabolic signals and the precise in-
terplay of these signaling pathways is crucial for the normal
function of the tissue. Therefore, the antagonistic relation-
ship between the pathways of proinﬂammatory cytokines,
such as IL-1b and TNF-a, and growth factors, such as
TGF-b, is a relevant topic in the study of chondrocyte biol-
ogy. Furthermore, the role of this counterbalance in the
pathogenesis of OA remains to be fully elucidated.
In general, proinﬂammatory cytokines are known to cause
a decrease in the expression of cartilage-speciﬁc collagens,
proteoglycans and tissue inhibitors of metalloproteinases
(TIMPs), while concomitantly causing increases in the ex-
pression of matrix metalloproteinases, cyclooxygenases
and NO25e27. The regulation of the corresponding genes
by TNF-a and IL-1b in chondrocytes proceeds through sig-
nal transduction pathways that result in the activation of tran-
scription factors such as NF-kB, signal transducers and
activators of transcription (STATs) and AP-128e30. Recently,
other relevant signal transduction pathways such as Wnt
and the receptor for advanced glycation end products
(RAGE) have been also described to mediate the effects
of TNF-a and IL-1b in chondrocytes30,44. However, little is
known about other transcription factors which may be regu-
lated in chondrocytes by proinﬂammatory cytokines. Since,
identiﬁcation of gene regulatory factors involved in the re-
sponse of chondrocytes to inﬂammatory signals may yield
new therapeutic targets, we undertook a global screen of
changes in transcription factor DNA-binding activity in hu-
man OA chondrocytes in response to treatment with TNF-a
or IL-1b using a novel array-based proteomic approach. A
consistent and signiﬁcant decrease in the DNA-binding ac-
tivity of Smad3/4 and TR(DR-4) was observed in human
OA chondrocytes from three different OA patients following
treatment with either TNF-a or IL-1b. Smad3/4 DNA-binding
activity was also downregulated in human OA chondrocytes
treated with either TNF-a or IL-1b in EMSA analysis conﬁrm-
ing the results from the protein/DNA array. These ﬁndings
are in accordance with previous studies showing that the
IL-1b or TNF-a and the TGF-b pathways share an antago-
nistic relationship in different cell types22e24,31e34, however,
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Fig. 6. Reduction of TGF-b-induced Smad3/4 phosphorylation by IL-b. Human OA and bovine chondrocytes were treated with either TGF-b for
30 min, or pretreatedbeforeTGF-b treatmentwith IL-1b for 30 min, or treatedwith IL-1balone for 60 min.Nuclear extractswere thenpreparedand
subjected to Western analysis using anti-phospho-Smad2/3 antibodies. Western analysis shows that the levels of phospho-Smad2/3 are signif-
icantly reduced in IL-1b pretreated chondrocytes vs TGF-b treatment alone. b-Actin protein levels are shown as a control for protein loading and
transfer. The data shown are representative of two independent experiments.
Fig. 5. Reduction of TGF-b-induced Smad3/4 DNA-binding activity by IL-b. (A) Nuclear extracts from bovine articular chondrocytes were ex-
amined by EMSA with a probe containing a consensus site for NF-kB, showing a marked increase in the NF-kB DNA-binding activity in the
cells treated with IL-1b alone and in the cells pretreated with IL-1b followed by TGF-b stimulation compared with control cells. Note that TGF-b
alone had only minimal effect. NP: no nuclear protein; M: mutant probe. (B) The same nuclear extracts were subjected to EMSA with a probe
containing a consensus site for Smad3/4. The EMSA shows that treatment with TGF-b caused induction in Smad3/4 DNA-binding activity,
whereas pretreatment with IL-1b reduced the TGF-b-induced Smad3/4 DNA-binding activity.
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only mildly affected by TGF-b or IL-1b. b-Actin protein levels are shown as a control for protein loading and transfer.counteraction is more potently exerted by TGF-b on IL-1b
than by IL-1b on TGF-b regulated genes45, although the
TGF-b counteraction on IL-1b-mediated effects is lost with
aging46. In addition, it is also notable that Smad3/ mice
develop a degenerative joint disease that resembles OA,
with progressive loss of articular cartilage, decreased pro-
duction of proteoglycans, abnormally increased number of
type X collagen-expressing chondrocytes, and hypertro-
phic-like changes in their articular cartilage7. Taken to-
gether, these ﬁndings provide an additional evidence of
the important anabolic-maintenance role of TGF-b Smad-
dependent signaling in normal articular cartilage metabolism
and in the pathogenesis of OA.
Here, we studied the modulation by IL-1b of the
response of human OA and bovine articular chondrocytesto TGF-b through regulation of Smad protein activity and
availability. Our results showed that IL-1b counteracts
TGF-b-induced Smad3/4 DNA-binding activity and
Smad2/3 phosphorylation providing additional evidence to
support the hypothesis that proinﬂammatory cytokines
such as IL-1b and TNF-a exert an antagonistic interaction
with TGF-b signaling through a Smad-dependent pathway.
This interaction is an important component of the counter-
balance between catabolic and anabolic mechanisms,
which occurs in normal cartilage and is disrupted in degen-
erative cartilage diseases.
Several cell-type speciﬁc mechanisms have been de-
scribed to be responsible for the counteraction among
the proinﬂammatory cytokines (IL-1b and TNF-a) and
the TGF-b growth factor pathways in numerous cell
1375Osteoarthritis and Cartilage Vol. 15, No. 12Fig. 8. (A) Diagram showing the potential sites of modulation of the TGF-b signaling pathway by IL-1b or TNF-a in articular chondrocytes.
Modulation may occur through mechanisms other than NF-kB/Smad7 activation including: 1 and 2. Enhancement of ubiquitination and/or
proteasome-mediated degradation of Smad proteins and type I TGF-b receptors. Smad proteins can be targeted for ubiquitination at different
points in the TGF-b signaling pathway; in the cytoplasm by Smurf E3 ligases, or in the nucleus by SCF class of E3 ubiquitin ligase complexes.
Type I TGF-b receptors can be ubiquitinated by Smurf E3 ligases interacting with I-Smads. Further degradation by the 26S proteasome follows
the ubiquitination process17e20,30,31. 3. Interfering the interactions between Smad-activated TGF-b target genes and other transcription fac-
tors, co-activators and co-repressors. Transcription factors that interact with Smads include the JNK-dependent activated AP-1
(c-Jun)27,28, as well as, co-repressors such as cSki/SnoN, c-Myc, Evi1, ATF3, TGFb-induced factor (TGIF), Smad nuclear interacting protein
1 (SNIP1), Smad interacting transcription factor (SIP1) and anti-proliferative protein Tob (Tob)15,16. 4. Inhibitory effect upon Smad3 phosphor-
ylation. (B) Postulated mechanisms responsible for inhibition of Smad phosphorylation. TGF-b activated kinase 1 (TAK1) can directly inhibit
Smad3 phosphorylation or can activate the JNK pathway leading to the formation of a c-JuneSmad3 complex not compatible with
Smad3eDNA interaction48,53.types22e24,31e34,47,48. However, the understanding of these
mechanisms in articular chondrocytes is limited. The most
extensively characterized mechanism of interaction in other
non-chondrocytic cell types involves NF-kB and Smad7. In-
hibitory Smads are expressed in normal and OA human
cartilage and regulate differentially TGF-b effects in chon-
drocytes. While Smad7 over-expression completely inhibits
TGF-b-induced stimulation of chondrocyte proliferation and
proteoglycan synthesis, Smad6 over-expression does not
or only partially inhibits these TGF-b effects49,50. However,
in experimental OA Smad6 and Smad7 over-expression
causes a signiﬁcant reduction in osteophyte formation and
in synovial thickening. Furthermore, Smad7 over-
expression maintains TGF-b-induced cartilage repair but
blocks synovial ﬁbrosis in a similar OA model51,52.
It has been previously shown that IL-1b/TNF-a signaling
can reduce the activity of TGF-b-induced responses
through increased expression or activity of NF-kB and/or
Smad733,47. In contrast, our results show that the stimulated
levels of Smad7 cytoplasmic mRNA and total Smad7 pro-
tein in TGF-b treated-cells are partially reversed by IL-1b
in human OA chondrocytes [Fig. 7(A)] suggesting that the
inhibitory Smad7 may not play a prominent role in the an-
tagonism between the proinﬂammatory cytokines IL-1b or
TNF-a and TGF-b signaling pathways in articular chondro-
cytes. This observation is similar to that obtained in A549
lung carcinoma cells48. Therefore, our results strongly indi-
cate that other alternative mechanisms by which IL-1b and
TNF-amodulate TGF-b-induced Smad3/4 activity and avail-
ability in articular chondrocytes must exist and need to
be explored. The potential mechanisms of interaction be-
tween IL-1b and TNF-a and the TGF-b pathways are dia-
grammatically represented in Fig. 8(A) and (B) includingactivation of Jun/AP-1/JNK pathway, enhancement of ubiq-
uitination and proteasome activity, and regulation of Smad-
co-repressor levels or interactions.
The balance between the IL-1/TNF-a and the TGF-b sig-
naling pathways is crucial for maintenance of articular carti-
lage homeostasis and its disruption likely plays an important
role in the pathogenesis of OA. The ﬁndings from this study
indicate that novel mechanisms may be involved in the sup-
pression of TGF-b signaling induced by IL-1b or TNF-a in
articular chondrocytes. A thorough understanding of the
mechanisms by which these two pathways interact and reg-
ulate one another is paramount toward elucidating the mo-
lecular events involved in the breakdown of articular
cartilage function during degenerative joint disease. Thus,
a precise knowledge of the events involved in the cross-
modulation of the anabolic TGF-b signaling pathway by
catabolic proinﬂammatory cytokines could allow the identiﬁ-
cation of novel targets for pharmacological intervention of
degenerative and inﬂammatory joint diseases.
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